Lightlake Therapeutics Inc. Retains KCSA Strategic Communications as Corporate Communications Advisors

LONDON, Aug. 5, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc., ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has retained KCSA Strategic Communications ("KCSA"), a leading New York-based communications firm, to direct the Company's investor and public relations programs.

KCSA will deploy an integrated investor and public relations campaign to increase awareness of Lightlake and its treatments for Binge Eating Disorder ("BED"), for Bulimia Nervosa ("BN"), and for the complications of drug addiction. The campaign will focus on the various influencers in the healthcare sector, in addition to outreach to business and key trade publications.

KCSA has garnered a strong reputation through four decades of experience representing domestic and international companies across all industries, including healthcare services and biopharmaceuticals. Managing Partners Todd Fromer and Lewis Goldberg will head up the account and provide strategic guidance on financial and media communication.

"We understand the importance of a proactive communications program to effectively reach the investment community, our shareholders, and the appropriate media. As we continue to grow our business and develop modern treatments for addiction diseases, we look forward to working closely with KCSA to effectively communicate our growth potential. We have exciting treatments in our pipeline that are in advanced stage clinical trials, providing us with significant short-term and long-term opportunities that can act as catalysts for our business. With KCSA's guidance, we hope to highlight the ongoing development of these treatments to our shareholders and the potential value they could have upon receiving regulatory market clearance," said Dr. Roger Crystal, Chief Executive Officer of Lightlake.

"We believe our experience with other biopharmaceutical companies and subsequent success with providing an integrated communications platform makes KCSA uniquely qualified to communicate Lightlake's growth potential," said Mr. Fromer. "Addiction affects millions of people and their families in the United States alone, and we are enthusiastic about increasing awareness of Lightlake and its treatment pipeline."

To be added to the Lightlake Therapeutics investor email list, please email pcarlson@kcsa.com with LLTP in the subject line.

About Lightlake Therapeutics
Lightlake Therapeutics Inc., a London-based biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative solutions to common addictions and related disorders. The Company holds patents covering the use of intranasal naloxone to treat Binge Eating Disorder ("BED") as well as patents covering addiction to drugs including cocaine, amphetamine, and MDMA. Lightlake is currently focused on advancing its treatment for BED, which has successfully completed Phase II clinical trials, and a Phase II trial is planned for the indication of Bulimia Nervosa. Lightlake is also applying its technology to develop a treatment for managing the complications of opioid drug addiction in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. For more information please visit: http://www.lightlaketherapeutics.com

About KCSA Strategic Communications
KCSA is a fully-integrated communications agency specializing in public relations, investor relations and marketing with expertise in financial and professional services, technology, healthcare, media, energy and public services companies. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm's clients are its best references. For more information, please visit www.kcsa.com.

Investor Relations Contact:
Phil Carlson / Josh Dver
KCSA Strategic Communications
212-896-1233 / 212-896-1239
pcarlson@kcsa.com / jdver@kcsa.com

Public Relations Contact:
Anne Donohoe / Taylor McGrann
KCSA Strategic Communications
212-896-1261 / 212-896-1253
adonohoe@kcsa.com / tmcgrann@kcsa.com

SOURCE Lightlake Therapeutics Inc.